Largest prospective clinical trial to-date in a rare subtype of GISTROCKVILLE, Md. and SUZHOU, China, (GLOBE NEWSWIRE) -- ...

GISTs are a rare type of cancer that develops in the digestive tract’s connective tissue, specifically from cells that help regulate muscle contractions. GISTs are primarily driven by genetic ...

GISTs are solid tumors, primarily in the stomach, characterized by KIT and EGFR mutations, with Gleevec as a key treatment.

NEW YORK, March 18, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company, today announced breakthrough preclinical findings demonstrating the ...

Unlike most GI cancers, GIST starts in supportive stromal tissue, not surface cells, and is classified as a sarcoma, says Dr. Weijing Sun. Gastrointestinal stromal tumor (GIST) is a rare type of ...

Less than 5% of GI stromal tumors (GISTs) are driven by the loss of the succinate dehydrogenase (SDH) complex, resulting in a pervasive DNA hypermethylation pattern that leads to unique clinical ...

This trial represents the first major advancement in second-line GIST treatment in over two decades, potentially transforming the therapeutic landscape. Cogent Biosciences announced positive results ...

The optimal duration of adjuvant imatinib has yet to be determined, and clinical trials are ongoing to address this. KIT-directed tyrosine kinase inhibitors (TKIs) are the key treatment for advanced ...

We recently published 10 Market Movers That Made Millionaires in a Week. Cogent Biosciences, Inc. (NASDAQ:COGT) is one of the ...

New Data Demonstrates Significant Reduction in Tumor Growth and KIT Expression in Preclinical GIST Models Induction of Tumor Cell Death – HT-KIT triggered significant tumor cell death as early as 24 ...